| View Question |
|
|
 | ||
|
| Subject:
Tablet/ Pill Production
Category: Miscellaneous Asked by: blucken-ga List Price: $50.00 |
Posted:
13 Jul 2006 11:00 PDT
Expires: 12 Aug 2006 11:00 PDT Question ID: 745992 |
Main Question: How many tablets/ pills are produced annually in the US? This would include pharma based drugs (generic and branded), OTC (other the counter drugs) and supplements/ vitamins (nutraceuticals). Number of pills would be great - value of the pills also would be nice. Also - bonus information would include what percent are specifially colored/ branded with a color or other effect. | |
| |
| |
|
| ||
|
| Subject:
Re: Tablet/ Pill Production
Answered By: czh-ga on 19 Jul 2006 09:34 PDT Rated:  |
Hello blucken-ga, I'm sorry the information you're looking for is not available. Thanks for accepting my answer at a modified price. ~ czh ~ ------------------------------------------------------ Hello blucken-ga, This has proved to be a very difficult search. The count for how many pills or tablets are produced annually in the US has proved very elusive. I haven?t found anything beyond statements asserting that Americans consume millions/billions of pills. This doesn?t mean that there isn?t lots of information available about the national and global pharmaceutical industry and some indications of the volume of pill production. The information you?re looking for might be available in the numerous very high priced market research reports that cover this industry. Unfortunately, very little of the contents of these reports is referenced in the business or trade press. I would be happy to provide you with links to these if you?re interested. ============ SOLID DOSAGE ============ I discovered in the course of my research that the major category for the medications you?re looking for is ?solid dosage forms/units? and it includes tablets and capsules of various forms and some new categories of quick dissolve films. http://www.fda.gov/cder/guidance/cmc5.pdf Drug Product A drug product is a finished dosage form (e.g., tablet, capsule, or solution) that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients [21 CFR 314.3(b)]. A solid oral dosage form includes tablets, chewable tablets, capsules, and soft gelatin capsules. == http://www.fda.gov/cder/dsm/DRG/drg00201.htm Data Element Name. Dosage Form. Description. This standard provides for all drug dosage forms. == http://www.upm.edu.ph/cp/ip/solids.htm PHARMACEUTICAL SOLID DOSAGE FORMS Currently, tablets may be considered the most popular dosage form. There are several types of tablets available commercially, these include: the Compressed Tablet (CT), Sugarcoated Tablets (SCT), Film Coated Tablet (FCT), Enteric-Coated Tablet (ECT), Multiple Compressed Tablet (MCT), Controlled-Release Tablet, Tablets for Solution, Effervescent Tablet, Compressed Suppositories or Inserts, Buccal and Sublingual Tablet. ========================================================= SOLID DOSAGE (PILLS, TABLETS, CAPSULES) PRODUCTION VOLUME ========================================================= Using a variety of search terms I was able to find information about tablet/pill production worldwide for specific factories or manufacturing plants. It seems no one has consolidated this information into statistics that match your queries. This search revealed that there are a lot of changes happening in the production of medicines. One of the biggest trends is the movement to outsourcing of manufacturing to third world plants, especially China and India. Here are some sample reports showing the production capacity of newer plants. If this kind of information is of interest to you, I could locate more of these. http://dominoext.novartis.com/NC/NCPrRe01.nsf/9d19c6f07c24d6b9c1256bf1006da9aa/c0f8d00b7deacc4ac1256e9800417ff8?OpenDocument Sandoz strengthens global production network with three new facilities Vienna, May 18, 2004 ? Sandoz, the world's second largest supplier of generic medicines, is expanding its global production network with the opening of three new plants this month in Poland, India and Romania. The USD 80 million total investment will boost production capacity by three billion tablets and capsules, while creating approximately 500 jobs. == http://www.sipac.gov.cn/english/news/t20051101_12717.htm The Most Advanced Capsule Plant Starts Production in SIP Suzhou Capsugel Ltd., invested by Capsule Division of American Pfizer Pharmaceuticals Ltd. in Suzhou, is the largest producer of pharmaceutical capsules in China. On Oct. 28, the new plant built by SCL on the east of Jinji Lake, SIP, went into operation with annual output of 14 billion capsules, making SCL the most advanced capsule producer in the world. A leader of pharmaceutical capsule producers in the world, the century-old capsule division of Pflizer Pharmaceuticals Ltd. claims over 50% of global market share. == http://www.blonnet.com/2005/07/02/stories/2005070203280100.htm Jubilant buys 64 pc stake in US drug co Trinity Labs Trigen Laboratories manufactures generic dosage forms and has a USFDA approved manufacturing facility in Maryland, US. It has an annual production capacity of 650 million tablets and 35 million capsules that can be enhanced to one billion tablets a year. == http://www.blonnet.com/2004/05/20/stories/2004052002610400.htm Sandoz opens third plant in India The Kalwe plant has a production capacity of one billion tablets and capsules per annum and is expected to go on stream next month, he said. The plant could be scaled-up to produce five billion tablets and capsules, if required, he added. == http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-08-2000/0001382681&EDATE= Schering-Plough to Build Four New Facilities in Singapore; $450 Million (U.S.) Expansion Boosts Investment in Singapore to $750 Million (U.S.) The $450 million (U.S.) expansion project will bring the company's total investment in Singapore to approximately $750 million (U.S.), significantly adding to the Republic's growing life sciences industry. The oral solid dosage manufacturing facility will produce finished pharmaceutical products using active ingredients manufactured in the primary production facility. The oral solid dosage facility is expected to manufacture ezetimibe tablets and a combination of loratadine and montelukast sodium, both of which are the subject of U.S. joint ventures with Merck & Co., Inc. and undergoing clinical trials. == http://www.the-innovation-group.com/ChemProfiles/Acetylsalicylic%20Acid.htm Acetylsalicylic Acid As of February, 2003, there are no U.S. producers of acetylsalicylic acid. Rhodia, the leading global aspirin producer, closed the last remaining acetylsalicylic acid plant in the U.S. in February of this year, eliminating 20 million pounds of annual capacity. The company maintains aspirin production units at Saint Fons, France, and Bangpoo, Thailand. DEMAND 2001: 23.8 million pounds; 2002: 23.9 million pounds; 2006: 24.3 million pounds, projected. Demand equals production plus imports (2001: 6.2 million pounds; 2002: 6.8 million pounds) less exports (2001: 0.9 million pounds; 2002: 0.9 million pounds). STRENGTH Aspirin remains a popular drug with 25 percent share of the total OTC analgesic market. == http://www.pharmaceutical-industry.info/modules/pharmaceutical_projects/projects_astrazeneca_vup25caxxpyzc545ek3sme45.html AstraZeneca Opens New US$37.8 (£26) Million Tablets Expansion Facility == http://www.pharmabiz.com/article/detnews.asp?articleid=34166 July 11, 2006 -- DRL to increase production capacity to 10 bn tablets and capsules ============================================================ SOLID DOSAGE (PILLS, TABLETS, CAPSULES) MANUFACTURING MARKET ============================================================ I was able to find some information about the size of the solid dosage medications market. Lots of additional information is available on this topic in the expensive market research reports. Please let me know if you want a selection of the most relevant ones. The table of contents gives you some hint of how the industry is defined even if it doesn?t give you the financial figures. http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037 Outsourcing Solid Dosage Manufacturing, Jun 2, 2006 Contract manufacturers expand production capacity, and opportunities arise in high potency and fast-dissolving formulations. And, the oral thin film emerges as a dosage form. Solid-dosage forms represent an established sector in the secondary manufacturing market. Annual global expenditures for commercial pharmaceutical manufacturing for finished-dosage forms is estimated at $83 billion, of which between $8?12 billion is outsourced, according to industry estimates offered by Patheon, Inc. (Mississauga, ON, Canada, www.patheon.com/) in its 2005 annual report. Roughly $3 billion is spent on dosage-form development, of which roughly $1 billion is outsourced. ============================================================= SOLID DOSAGE (PILLS, TABLETS, CAPSULES) FORMS, COLORS, SHAPES ============================================================= There is quite a bit of information about developments in this area of your quest. Most pharmaceutical companies are looking for ways to extend the profitability of their products so they?re looking for new forms of drug delivery. I?m also including here some information about pill identification and the importance of color/shape/form for the branding of medications. http://asia.pharmtech.com/pharmtechasia/article/articleDetail.jsp?id=321547&searchString=tablets Orally Disintegrating Tablets, Apr 20, 2006 Over the past three decades, orally disintegrating tablets (ODTs) have gained much attention as a preferred alternative to conventional oral dosage forms such as tablets and capsules. An ODT is a solid dosage form that disintegrates and dissolves in the mouth (either on or beneath the tongue or in the buccal cavity) without water within 60 seconds or less. The US Food and Drug Administration Center for Drug Evaluation and Research (CDER) defines in the Orange Book an ODT as "A solid dosage form containing medicinal substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue" Recent market studies indicate that more than half of the patient population prefers ODTs to other dosage forms (6) and most consumers would ask their doctors for ODTs (70%), purchase ODTs (70%), or prefer ODTs to regular tablets or liquids (>80%) (7). These responses may, in part, be attributed to known ODT advantages such as ease of administration, ease of swallowing, pleasant taste, and the availability of several flavors (8). ODTs also offer clinical advantages such as improved safety and, in some cases, improved efficacy and other broader indications. In addition, several business needs are driving ODT technology development and the commercialization of new products such as the need for expanded product lines, improved life-cycle management, extended patent life, and marketing advantages. ----- http://asia.pharmtech.com/pharmtechasia/data/articlestandard//pharmtechasia/172006/321547/i3.gif Table I: Summary of orally disintegrating tablet products on the US market (3, 5). == http://en.wikipedia.org/wiki/Tablet http://en.wikipedia.org/wiki/Excipient == http://www.vonl.com/chips/phartab1.htm http://www.vonl.com/chips/phartab2.htm http://www.vonl.com/chips/phartab3.htm Pharmaceutical Dosage Forms: Tablets == http://www.colormatters.com/body_pills.html Taking the Color of Medications Seriously Pharmaceutical Color ? A New Frontier! == http://www.drugs.com/pill_identification.html Pill Identification Wizard == http://www.colorcon.com/best/index.htm The BEST integrated Brand Enhancement System for Tablets enables companies to produce distinctive, easy-to-recognize tablets with unique colors, shapes, markings and coatings. ----- http://www.colorcon.com/best/med_er_fin.pdf Medical Error Reduction with Distinctive Tablet Designs == http://www.answerbag.com/c_view.php/3598 Home » Index » Health & Fitness » Drugs & Medicine » Prescription drugs » What is this pill? ============================================== SOLID DOSAGE (PILLS, TABLETS, CAPSULES) TRENDS ============================================== These articles discuss current trends in solid dosage manufacturing. They provides information about the key players, industry consolidation and new developments worldwide. http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037 Outsourcing Solid Dosage Manufacturing, Jun 2, 2006 Industry fundamentals are positive Industry players point to several drivers in outsourcing secondary manufacturing. "Pharmaceutical sales continue to grow," outlines Doug Ludwig, Patheon's executive vice-president and chief financial officer, who spoke at a recent investors' conference in late April. He points to IMS Health's (Fairfield, CT, www.imshealth.com/) projected five-year compound annual growth rate of 5?8% for the global pharmaceutical market. Moreover, "a major trend in the solid-dosage market is the number of large pharmaceutical companies looking to outsource their solid-dosage products as a result of rationalizing their own facilities," observes Terry Novak, business director at DSM Pharmaceuticals, Inc. (Parsippany, NJ, www.dsm.com/). "In solid-dosage manufacturing, we see two key trends," explains Colin Minchom, Patheon's vice-president of pharmaceutical development services, Canada. "One is toward lower dose, high-potency formulations, and the second is demand for formulations for poorly soluble drugs. Our addition of capabilities for high-potency actives and liquid-fill hard capsules address both of these needs." Fast-melt technology advances Orally disintegrating tablets (ODTs) is another sector gaining momentum. "Another key trend is the increasing number of products being developed and commercialized using fast-melt technology," says DSM's Novak. The global ODT market (based on ex-factory sales to wholesalers) was $2.4 billion in 2004 and is expected to reach $3 billion in 2006, estimates the consultancy Technology Catalysts International (Falls Church, VA, www.technology-catalysts.com/). The technology is important in patient groups that may have difficulty swallowing conventional oral medications such as geriatric and pediatric patients or in the administration of certain central nervous systems drugs. Candidates for oral thin-film delivery The 2004 global market (based on ex-factory sales to wholesalers) for OTF technology in pharmaceutical (OTC) and nutraceutical products was estimated at $25 million, says Technology Catalysts. The market is projected to increase to $500 million by 2007, conditioned on the entry of higher revenue-generating OTC products and possibly prescription drug products entering the market. == http://www.contractpharma.com/articles/2006/03/solid-dosage-manufacturing.php Solid Dosage Manufacturing ? Opportunities abound for solid dose CMSs Solid dosage may not be as sexy as some of the novel drug delivery forms of recent years, but they remain far and away the prevalent dosage form on the market. The contract manufacturing market for them continues to grow, spurred on partly by new, smaller entrants into the marketplace, product line extensions, and large Pharma companies? need to rethink their manufacturing platforms. ?Today, with more solid dose products being based on high active compounds, the typical dosing regimen for a patient is BID, or one tablet per day. Large Pharma companies are still tooled to make the huge batches, but with high active-based solid dose product, the manufacturing need is for smaller batches, based on flexible capabilities and flexible processes. This is where the third-party producers are aligning their processes.? -- Key Drivers -- Extending the Market -- Brand X (generics) -- Money Talks (investments in new plants) == http://www.pharmpro.com/ShowPR.aspx?PUBCODE=021&ACCT=0000100&ISSUE=0601&RELTYPE=PR&ORIGRELTYPE=ATO&PRODCODE=0000&PRODLETT=A Designing For the Future of Continuous Processing The FDA?s initiative promoting continuous processing systems for the pharmaceutical industry and its subsequent PAT guidelines are helping to promote a revolution in solid dosage pharmaceuticals manufacturing methods and facility design. Promising improved yields, increased quality control, better inventory management and vast improvements in lead times by moving from current batch technology toward continuous manufacturing processes, the FDA has removed the last great roadblock to innovation in the solid dosage manufacturing industry, Regulatory Constraint. The move to process innovation in solid dosage manufacturing is long overdue. For many years, the solid dosage pharmaceutical industry enjoyed high profit margins, overall market control and a regulatory environment that stifled competition, lessening the need to look to innovative methods to produce their product. In the last five years, however, the reality of the changing marketplace forced manufacturers to seek out ways to better compete, retain profitability, improve quality and continue to increase shareholder returns. An ongoing study by O?Neal?s Advanced Technology Research Group confirms that new solid dosage facilities will be much smaller, cost less to construct and require much less labor and energy to operate at current production levels. == http://www.frost.com/prod/servlet/report-brochure.pag?id=A918-01-00-00-00 Global Pharmaceutical Contract Manufacturing Markets Cost Pressure and Need for Greater Productivity Fuel Market Growth The global pharmaceutical industry is witnessing rapid advances in processes and technology, and automation is emerging an integral part of most manufacturing processes. With stricter regulatory norms and spiraling costs, pharmaceutical companies are opting to outsource their manufacturing process to contract manufacturing organizations (CMOs) in order to improve efficiency and productivity. The pharmaceutical contract manufacturing market is moving beyond providing traditional services, and is focusing on tapping the large demand for specialized niche technologies. CMOs have been building state-of-the-art facilities that rival those of pharmaceutical companies and are constantly upgrading them to enable novel manufacturing processes. Pharmaceutical companies are increasingly adopting the concept of ?virtual pharma?, wherein they retain the marketing rights while outsourcing all manufacturing activities and related processes. This allows companies to deliver goods to the market at a faster rate than an internal plant would allow. "Among the dosage forms, solid dosage forms are continuing to lead revenue contribution, whereas liquid dosage forms are expected to lose their market share to injectables that primarily include sterile products and biopharmaceuticals (primarily oncology)." == http://www.libraries.psu.edu/business/industryguides/pharmaceutical.htm Pharmaceutical and Medicine Manufacturing Industry -- NAICS 3254 Blucken-ga, I hope that the information I?ve found will be useful. If you need additional information based on my findings I?ll be happy to continue the search. Please let me know if I can post this as an official answer. All the best. ~ czh ~ |
| blucken-ga
rated this answer:
|
| ||
|
| Subject:
Re: Tablet/ Pill Production
From: czh-ga on 17 Jul 2006 17:01 PDT |
Hello blucken-ga, This has proved to be a very difficult search. The count for how many pills or tablets are produced annually in the US has proved very elusive. I haven?t found anything beyond statements asserting that Americans consume millions/billions of pills. This doesn?t mean that there isn?t lots of information available about the national and global pharmaceutical industry and some indications of the volume of pill production. The information you?re looking for might be available in the numerous very high priced market research reports that cover this industry. Unfortunately, very little of the contents of these reports is referenced in the business or trade press. I would be happy to provide you with links to these if you?re interested. ============ SOLID DOSAGE ============ I discovered in the course of my research that the major category for the medications you?re looking for is ?solid dosage forms/units? and it includes tablets and capsules of various forms and some new categories of quick dissolve films. http://www.fda.gov/cder/guidance/cmc5.pdf Drug Product A drug product is a finished dosage form (e.g., tablet, capsule, or solution) that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients [21 CFR 314.3(b)]. A solid oral dosage form includes tablets, chewable tablets, capsules, and soft gelatin capsules. == http://www.fda.gov/cder/dsm/DRG/drg00201.htm Data Element Name. Dosage Form. Description. This standard provides for all drug dosage forms. == http://www.upm.edu.ph/cp/ip/solids.htm PHARMACEUTICAL SOLID DOSAGE FORMS Currently, tablets may be considered the most popular dosage form. There are several types of tablets available commercially, these include: the Compressed Tablet (CT), Sugarcoated Tablets (SCT), Film Coated Tablet (FCT), Enteric-Coated Tablet (ECT), Multiple Compressed Tablet (MCT), Controlled-Release Tablet, Tablets for Solution, Effervescent Tablet, Compressed Suppositories or Inserts, Buccal and Sublingual Tablet. ========================================================= SOLID DOSAGE (PILLS, TABLETS, CAPSULES) PRODUCTION VOLUME ========================================================= Using a variety of search terms I was able to find information about tablet/pill production worldwide for specific factories or manufacturing plants. It seems no one has consolidated this information into statistics that match your queries. This search revealed that there are a lot of changes happening in the production of medicines. One of the biggest trends is the movement to outsourcing of manufacturing to third world plants, especially China and India. Here are some sample reports showing the production capacity of newer plants. If this kind of information is of interest to you, I could locate more of these. http://dominoext.novartis.com/NC/NCPrRe01.nsf/9d19c6f07c24d6b9c1256bf1006da9aa/c0f8d00b7deacc4ac1256e9800417ff8?OpenDocument Sandoz strengthens global production network with three new facilities Vienna, May 18, 2004 ? Sandoz, the world's second largest supplier of generic medicines, is expanding its global production network with the opening of three new plants this month in Poland, India and Romania. The USD 80 million total investment will boost production capacity by three billion tablets and capsules, while creating approximately 500 jobs. == http://www.sipac.gov.cn/english/news/t20051101_12717.htm The Most Advanced Capsule Plant Starts Production in SIP Suzhou Capsugel Ltd., invested by Capsule Division of American Pfizer Pharmaceuticals Ltd. in Suzhou, is the largest producer of pharmaceutical capsules in China. On Oct. 28, the new plant built by SCL on the east of Jinji Lake, SIP, went into operation with annual output of 14 billion capsules, making SCL the most advanced capsule producer in the world. A leader of pharmaceutical capsule producers in the world, the century-old capsule division of Pflizer Pharmaceuticals Ltd. claims over 50% of global market share. == http://www.blonnet.com/2005/07/02/stories/2005070203280100.htm Jubilant buys 64 pc stake in US drug co Trinity Labs Trigen Laboratories manufactures generic dosage forms and has a USFDA approved manufacturing facility in Maryland, US. It has an annual production capacity of 650 million tablets and 35 million capsules that can be enhanced to one billion tablets a year. == http://www.blonnet.com/2004/05/20/stories/2004052002610400.htm Sandoz opens third plant in India The Kalwe plant has a production capacity of one billion tablets and capsules per annum and is expected to go on stream next month, he said. The plant could be scaled-up to produce five billion tablets and capsules, if required, he added. == http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-08-2000/0001382681&EDATE= Schering-Plough to Build Four New Facilities in Singapore; $450 Million (U.S.) Expansion Boosts Investment in Singapore to $750 Million (U.S.) The $450 million (U.S.) expansion project will bring the company's total investment in Singapore to approximately $750 million (U.S.), significantly adding to the Republic's growing life sciences industry. The oral solid dosage manufacturing facility will produce finished pharmaceutical products using active ingredients manufactured in the primary production facility. The oral solid dosage facility is expected to manufacture ezetimibe tablets and a combination of loratadine and montelukast sodium, both of which are the subject of U.S. joint ventures with Merck & Co., Inc. and undergoing clinical trials. == http://www.the-innovation-group.com/ChemProfiles/Acetylsalicylic%20Acid.htm Acetylsalicylic Acid As of February, 2003, there are no U.S. producers of acetylsalicylic acid. Rhodia, the leading global aspirin producer, closed the last remaining acetylsalicylic acid plant in the U.S. in February of this year, eliminating 20 million pounds of annual capacity. The company maintains aspirin production units at Saint Fons, France, and Bangpoo, Thailand. DEMAND 2001: 23.8 million pounds; 2002: 23.9 million pounds; 2006: 24.3 million pounds, projected. Demand equals production plus imports (2001: 6.2 million pounds; 2002: 6.8 million pounds) less exports (2001: 0.9 million pounds; 2002: 0.9 million pounds). STRENGTH Aspirin remains a popular drug with 25 percent share of the total OTC analgesic market. == http://www.pharmaceutical-industry.info/modules/pharmaceutical_projects/projects_astrazeneca_vup25caxxpyzc545ek3sme45.html AstraZeneca Opens New US$37.8 (£26) Million Tablets Expansion Facility == http://www.pharmabiz.com/article/detnews.asp?articleid=34166 July 11, 2006 -- DRL to increase production capacity to 10 bn tablets and capsules ============================================================ SOLID DOSAGE (PILLS, TABLETS, CAPSULES) MANUFACTURING MARKET ============================================================ I was able to find some information about the size of the solid dosage medications market. Lots of additional information is available on this topic in the expensive market research reports. Please let me know if you want a selection of the most relevant ones. The table of contents gives you some hint of how the industry is defined even if it doesn?t give you the financial figures. http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037 Outsourcing Solid Dosage Manufacturing, Jun 2, 2006 Contract manufacturers expand production capacity, and opportunities arise in high potency and fast-dissolving formulations. And, the oral thin film emerges as a dosage form. Solid-dosage forms represent an established sector in the secondary manufacturing market. Annual global expenditures for commercial pharmaceutical manufacturing for finished-dosage forms is estimated at $83 billion, of which between $8?12 billion is outsourced, according to industry estimates offered by Patheon, Inc. (Mississauga, ON, Canada, www.patheon.com/) in its 2005 annual report. Roughly $3 billion is spent on dosage-form development, of which roughly $1 billion is outsourced. ============================================================= SOLID DOSAGE (PILLS, TABLETS, CAPSULES) FORMS, COLORS, SHAPES ============================================================= There is quite a bit of information about developments in this area of your quest. Most pharmaceutical companies are looking for ways to extend the profitability of their products so they?re looking for new forms of drug delivery. I?m also including here some information about pill identification and the importance of color/shape/form for the branding of medications. http://asia.pharmtech.com/pharmtechasia/article/articleDetail.jsp?id=321547&searchString=tablets Orally Disintegrating Tablets, Apr 20, 2006 Over the past three decades, orally disintegrating tablets (ODTs) have gained much attention as a preferred alternative to conventional oral dosage forms such as tablets and capsules. An ODT is a solid dosage form that disintegrates and dissolves in the mouth (either on or beneath the tongue or in the buccal cavity) without water within 60 seconds or less. The US Food and Drug Administration Center for Drug Evaluation and Research (CDER) defines in the Orange Book an ODT as "A solid dosage form containing medicinal substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue" Recent market studies indicate that more than half of the patient population prefers ODTs to other dosage forms (6) and most consumers would ask their doctors for ODTs (70%), purchase ODTs (70%), or prefer ODTs to regular tablets or liquids (>80%) (7). These responses may, in part, be attributed to known ODT advantages such as ease of administration, ease of swallowing, pleasant taste, and the availability of several flavors (8). ODTs also offer clinical advantages such as improved safety and, in some cases, improved efficacy and other broader indications. In addition, several business needs are driving ODT technology development and the commercialization of new products such as the need for expanded product lines, improved life-cycle management, extended patent life, and marketing advantages. ----- http://asia.pharmtech.com/pharmtechasia/data/articlestandard//pharmtechasia/172006/321547/i3.gif Table I: Summary of orally disintegrating tablet products on the US market (3, 5). == http://en.wikipedia.org/wiki/Tablet http://en.wikipedia.org/wiki/Excipient == http://www.vonl.com/chips/phartab1.htm http://www.vonl.com/chips/phartab2.htm http://www.vonl.com/chips/phartab3.htm Pharmaceutical Dosage Forms: Tablets == http://www.colormatters.com/body_pills.html Taking the Color of Medications Seriously Pharmaceutical Color ? A New Frontier! == http://www.drugs.com/pill_identification.html Pill Identification Wizard == http://www.colorcon.com/best/index.htm The BEST integrated Brand Enhancement System for Tablets enables companies to produce distinctive, easy-to-recognize tablets with unique colors, shapes, markings and coatings. ----- http://www.colorcon.com/best/med_er_fin.pdf Medical Error Reduction with Distinctive Tablet Designs == http://www.answerbag.com/c_view.php/3598 Home » Index » Health & Fitness » Drugs & Medicine » Prescription drugs » What is this pill? ============================================== SOLID DOSAGE (PILLS, TABLETS, CAPSULES) TRENDS ============================================== These articles discuss current trends in solid dosage manufacturing. They provides information about the key players, industry consolidation and new developments worldwide. http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=333037 Outsourcing Solid Dosage Manufacturing, Jun 2, 2006 Industry fundamentals are positive Industry players point to several drivers in outsourcing secondary manufacturing. "Pharmaceutical sales continue to grow," outlines Doug Ludwig, Patheon's executive vice-president and chief financial officer, who spoke at a recent investors' conference in late April. He points to IMS Health's (Fairfield, CT, www.imshealth.com/) projected five-year compound annual growth rate of 5?8% for the global pharmaceutical market. Moreover, "a major trend in the solid-dosage market is the number of large pharmaceutical companies looking to outsource their solid-dosage products as a result of rationalizing their own facilities," observes Terry Novak, business director at DSM Pharmaceuticals, Inc. (Parsippany, NJ, www.dsm.com/). "In solid-dosage manufacturing, we see two key trends," explains Colin Minchom, Patheon's vice-president of pharmaceutical development services, Canada. "One is toward lower dose, high-potency formulations, and the second is demand for formulations for poorly soluble drugs. Our addition of capabilities for high-potency actives and liquid-fill hard capsules address both of these needs." Fast-melt technology advances Orally disintegrating tablets (ODTs) is another sector gaining momentum. "Another key trend is the increasing number of products being developed and commercialized using fast-melt technology," says DSM's Novak. The global ODT market (based on ex-factory sales to wholesalers) was $2.4 billion in 2004 and is expected to reach $3 billion in 2006, estimates the consultancy Technology Catalysts International (Falls Church, VA, www.technology-catalysts.com/). The technology is important in patient groups that may have difficulty swallowing conventional oral medications such as geriatric and pediatric patients or in the administration of certain central nervous systems drugs. Candidates for oral thin-film delivery The 2004 global market (based on ex-factory sales to wholesalers) for OTF technology in pharmaceutical (OTC) and nutraceutical products was estimated at $25 million, says Technology Catalysts. The market is projected to increase to $500 million by 2007, conditioned on the entry of higher revenue-generating OTC products and possibly prescription drug products entering the market. == http://www.contractpharma.com/articles/2006/03/solid-dosage-manufacturing.php Solid Dosage Manufacturing ? Opportunities abound for solid dose CMSs Solid dosage may not be as sexy as some of the novel drug delivery forms of recent years, but they remain far and away the prevalent dosage form on the market. The contract manufacturing market for them continues to grow, spurred on partly by new, smaller entrants into the marketplace, product line extensions, and large Pharma companies? need to rethink their manufacturing platforms. ?Today, with more solid dose products being based on high active compounds, the typical dosing regimen for a patient is BID, or one tablet per day. Large Pharma companies are still tooled to make the huge batches, but with high active-based solid dose product, the manufacturing need is for smaller batches, based on flexible capabilities and flexible processes. This is where the third-party producers are aligning their processes.? -- Key Drivers -- Extending the Market -- Brand X (generics) -- Money Talks (investments in new plants) == http://www.pharmpro.com/ShowPR.aspx?PUBCODE=021&ACCT=0000100&ISSUE=0601&RELTYPE=PR&ORIGRELTYPE=ATO&PRODCODE=0000&PRODLETT=A Designing For the Future of Continuous Processing The FDA?s initiative promoting continuous processing systems for the pharmaceutical industry and its subsequent PAT guidelines are helping to promote a revolution in solid dosage pharmaceuticals manufacturing methods and facility design. Promising improved yields, increased quality control, better inventory management and vast improvements in lead times by moving from current batch technology toward continuous manufacturing processes, the FDA has removed the last great roadblock to innovation in the solid dosage manufacturing industry, Regulatory Constraint. The move to process innovation in solid dosage manufacturing is long overdue. For many years, the solid dosage pharmaceutical industry enjoyed high profit margins, overall market control and a regulatory environment that stifled competition, lessening the need to look to innovative methods to produce their product. In the last five years, however, the reality of the changing marketplace forced manufacturers to seek out ways to better compete, retain profitability, improve quality and continue to increase shareholder returns. An ongoing study by O?Neal?s Advanced Technology Research Group confirms that new solid dosage facilities will be much smaller, cost less to construct and require much less labor and energy to operate at current production levels. == http://www.frost.com/prod/servlet/report-brochure.pag?id=A918-01-00-00-00 Global Pharmaceutical Contract Manufacturing Markets Cost Pressure and Need for Greater Productivity Fuel Market Growth The global pharmaceutical industry is witnessing rapid advances in processes and technology, and automation is emerging an integral part of most manufacturing processes. With stricter regulatory norms and spiraling costs, pharmaceutical companies are opting to outsource their manufacturing process to contract manufacturing organizations (CMOs) in order to improve efficiency and productivity. The pharmaceutical contract manufacturing market is moving beyond providing traditional services, and is focusing on tapping the large demand for specialized niche technologies. CMOs have been building state-of-the-art facilities that rival those of pharmaceutical companies and are constantly upgrading them to enable novel manufacturing processes. Pharmaceutical companies are increasingly adopting the concept of ?virtual pharma?, wherein they retain the marketing rights while outsourcing all manufacturing activities and related processes. This allows companies to deliver goods to the market at a faster rate than an internal plant would allow. "Among the dosage forms, solid dosage forms are continuing to lead revenue contribution, whereas liquid dosage forms are expected to lose their market share to injectables that primarily include sterile products and biopharmaceuticals (primarily oncology)." == http://www.libraries.psu.edu/business/industryguides/pharmaceutical.htm Pharmaceutical and Medicine Manufacturing Industry -- NAICS 3254 Blucken-ga, I hope that the information I?ve found will be useful. If you need additional information based on my findings I?ll be happy to continue the search. Please let me know if I can post this as an official answer. All the best. ~ czh ~ |
If you feel that you have found inappropriate content, please let us know by emailing us at answers-support@google.com with the question ID listed above. Thank you. |
| Search Google Answers for |
| Google Home - Answers FAQ - Terms of Service - Privacy Policy |
